Outpatient transplantation in the COVID-19 era: a single-center Latin American experience

Colunga‐Pedraza, Perla R.; Colunga‐Pedraza, Julia E.; Meléndez-Flores, Jesús D.; González-Treviño, Mariana; León, Andrés Gómez‐De; Peña-Lozano, Samantha P.; González-Llano, Óscar; Cantú-Rodrı́guez, Olga Graciela; Bustillos-Muñoz, Mónica; Gutiérrez-Aguirre, César Homero; Gómez‐Almaguer, David; Jaime‐Pérez, José Carlos

doi:10.1038/s41409-021-01360-4

Cited by 5 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their incidence of SARS-CoV-2 infection was 8.6%. 35 Whether COVID-19 incidence is different among immunosuppressed patients is still controversial. On the one hand, it is possible that these patients are more susceptible to being infected and to being symptomatic.…”

Section: Variables Associated With Outcomesmentioning

confidence: 99%

Severe acute respiratory syndrome coronavirus 2 infection in hematopoietic stem cell transplant recipients in Mexico City

Martinez‐Rivera,

Franco,

Acosta‐Maldonado

et al. 2024

Transplant Infectious Dis

View full text Add to dashboard Cite

BackgroundHematopoietic stem cell transplant (HSCT) recipients are among patients with highest risk of adverse coronavirus disease 2019 (COVID‐19) outcomes.ObjectiveWe compared clinical outcomes in post‐HSCT patients with COVID‐19 before and during the Omicron period.Study DesignThis was a retrospective study including patients post‐HSCT with severe acute respiratory syndrome coronavirus 2 infection from April 2020 to March 2023 at Instituto Nacional de Cancerología, Mexico City. We describe their clinical characteristics and report the variables associated with severe clinical disease, hospitalization, and death.ResultsFifty‐three patients were included; 31 (58.5%) from the pre‐Omicron period and 22 (41.5%) from the Omicron period. Median age was 42‐years old (interquartile range 26–53), and 31 patients (59%) were men. Only four patients (16%) had received a vaccine prior to COVID‐19 diagnosis in the pre‐Omicron period versus 20 (91%) in the Omicron period (p < 0.001). COVID‐19 severe cases were more common before Omicron: seven patients (23%) versus two patients (9%). Only one patient (3%) received an antiviral in the pre‐Omicron period compared to 11 patients (50%) during the Omicron period (p < 0.01). COVID‐19‐associated mortality was almost double in the pre‐Omicron period (16% vs. 9%, p = 0.6).ConclusionsThis study reports patients with a high proportion of severe outcomes during the first 2 years of the pandemic. Outcomes improved during Omicron with better access to vaccines and antivirals and no in‐hospital cases. Variables associated with worse outcomes were similar to other reports. Strengthening infection control measures in the hospital and better access to preventive strategies and therapeutic options are mandatory in these high‐risk patients. image

show abstract

Section: Variables Associated With Outcomesmentioning

confidence: 99%

Severe acute respiratory syndrome coronavirus 2 infection in hematopoietic stem cell transplant recipients in Mexico City

Martinez‐Rivera,

Franco,

Acosta‐Maldonado

et al. 2024

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…After March 2020, we requested patients and caregivers isolate themselves 2 weeks before the procedure and encourage indoor masking within the residence if caregivers continued to have external contact with people other than the patient and the treatment center. When caregivers develop any symptoms suspicious of an upper respiratory infection, we ask that they leave the residence for appropriate testing and management; 36 meanwhile, another caregiver must be ready to help the patient.…”

Section: How Do We Perform Outpatient Allo-hsct?mentioning

confidence: 99%

Outpatient allogeneic hematopoietic stem-cell transplantation: a review

Gómez‐Almaguer

León

Colunga‐Pedraza

et al. 2022

Therapeutic Advances in Hematology

Self Cite

View full text Add to dashboard Cite

Hematopoietic stem-cell transplantation (HSCT) is usually performed in well-equipped units inside a hospital. The cost of this in-hospital transplant is usually very high; therefore, this procedure is more difficult to perform in low- and middle-income countries. Autologous outpatient HSCT is now a common procedure; however, outpatient allogeneic transplants are more complicated. Only a few centers in the world have incorporated outpatient HSCT. This transplant requires special adaptation, like a day hospital, careful selection of patients, oral medications, and the patient must live relatively close to the hospital. The results until now suggest that this outpatient transplant is factible and similar to inpatient HSCT. The objective was to review and describe the different methods and results following an outpatient allogeneic-HSCT strategy.

show abstract

Increasing access to transplantation through telemedicine and patient navigation

Gómez-De León,

Jiménez-Antolinez,

Rodríguez-González

et al. 2024

Cytotherapy

View full text Add to dashboard Cite

Outpatient transplantation in the COVID-19 era: a single-center Latin American experience

Cited by 5 publications

References 9 publications

Severe acute respiratory syndrome coronavirus 2 infection in hematopoietic stem cell transplant recipients in Mexico City

Severe acute respiratory syndrome coronavirus 2 infection in hematopoietic stem cell transplant recipients in Mexico City

Outpatient allogeneic hematopoietic stem-cell transplantation: a review

Increasing access to transplantation through telemedicine and patient navigation

Contact Info

Product

Resources

About